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Abstract
Background: The aim of this paper is to study the function of allogeneic and autologous NK cells against Dental Pulp Stem
Cells (DPSCs) and Mesenchymal Stem Cells (MSCs) and to determine the function of NK cells in a three way interaction with
monocytes and stem cells.
Methodology/Principal Findings: We demonstrate here that freshly isolated untreated or IL-2 treated NK cells are potent
inducers of cell death in DPSCs and MSCs, and that anti-CD16 antibody which induces functional split anergy and apoptosis
in NK cells inhibits NK cell mediated lysis of DPSCs and MSCs. Monocytes co-cultured with either DPSCs or MSCs decrease
lysis of stem cells by untreated or IL-2 treated NK cells. Monocytes also prevent NK cell apoptosis thereby raising the overall
survival and function of NK cells, DPSCs or MSCs. Both total population of monocytes and those depleted of CD16
+ subsets
were able to prevent NK cell mediated lysis of MSCs and DPSCs, and to trigger an increased secretion of IFN-c by IL-2 treated
NK cells. Protection of stem cells from NK cell mediated lysis was also seen when monocytes were sorted out from stem cells
before they were added to NK cells. However, this effect was not specific to monocytes since the addition of T and B cells to
stem cells also protected stem cells from NK cell mediated lysis. NK cells were found to lyse monocytes, as well as T and B
cells.
Conclusion/Significance: By increasing the release of IFN-c and decreasing the cytotoxic function of NK cells monocytes are
able to shield stem cells from killing by the NK cells, resulting in an increased protection and differentiation of stem cells.
More importantly studies reported in this paper indicate that anti-CD16 antibody can be used to prevent NK cell induced
rejection of stem cells.
Citation: Jewett A, Arasteh A, Tseng H-C, Behel A, Arasteh H, et al. (2010) Strategies to Rescue Mesenchymal Stem Cells (MSCs) and Dental Pulp Stem Cells
(DPSCs) from NK Cell Mediated Cytotoxicity. PLoS ONE 5(3): e9874. doi:10.1371/journal.pone.0009874
Editor: Jacques Zimmer, Centre de Recherche Public de la Sante ´ (CRP-Sante ´), Luxembourg
Received February 15, 2010; Accepted February 25, 2010; Published March 31, 2010
Copyright:  2010 Jewett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was received from the University of California Los Angeles Academic Senate grant. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ajewett@ucla.edu
Introduction
Previous reports demonstrated significant immunomodulatory
effect of Mesenchymal Stem Cells (MSCs) on different immune
effector subsets such as cytotoxic T cells and Natural Killer (NK)
cells [1,2,3,4,5]. Several reports have also indicated the immuno-
suppressive nature of MSCs on NK cells [4,6,7]. Moreover,
activated NK cells were shown to lyse MSCs significantly. In
particular, both allogeneic and autologous MSCs were shown to
be targets of NK cell mediated lysis [8,9]. Therefore, on one hand
the MSCs were shown to be immunosuppressive and on the other
they were found to be sensitive to lysis by the NK cells. Thus, these
diverse results prompted us to evaluate the function of NK cells
against two different types of stem cells, namely DPSCs and
MSCs. Although some information is known about the function of
NK cells against MSCs, no studies have been performed thus far
to determine the effect of NK cells on DPSCs. DPSCs were shown
to form colonies in vitro, and they were capable of osteogenic,
chondrogenic and adipogenic differentiation [10]. In order to find
ways to protect stem cells from lysis by the NK cells we need to
first determine the magnitude and the mechanisms by which NK
cells lyse stem cells and second to implement strategies based on
those findings to protect stem cells from NK cell lysis.
Many diverse mechanisms were hypothesized to mediate the
immunosuppressive effect of MSCs. TGFb and Hepatocyte
Growth Factor (HGF) were both shown to be the mediator of T
cell suppression by MSCs [11]. Leukemia Inhibitory Factor
induced in co-cultures of MSCs and lymphocytes was shown to
mediate suppression of T cell proliferation [12]. IFN-c induced by
T cells increased B7H1 inhibitory co-stimulatory receptors on
MSCs and resulted in the suppression of T cells [13].
Immunosuppressive function of MSCs is elicited by the combina-
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elevation in the levels of chemokines and inducible nitric oxide
(iNOS) [14]. Finally, indoleamine 2,3-dioxygenase (IDO) and
Prostaglandin E2 (PGE2) were also shown to be the key mediators
of MSC inhibition of NK cells [6]. Overall, these studies indicated
the inhibitory role of key factors induced during the interaction of
MSCs with the immune effectors.
We have previously coined the term of ‘‘split anergy’’ for the
responses observed by NKDC (NK cells dissociated from tumor
conjugates) and NKC (NK cells not dissociated from the tumor
conjugate). Whereas NKDC responded to IL-2 activation for
cytotoxicity, they were unresponsive to IL-2 mediated induction of
proliferation or secretion of cytokines. In contrast, NKC showed an
inverse response namely, they did not respond to IL-2 activation
for cytotoxicity, but proliferated and secreted cytokines [15,16].
Treatment of NK cells with IL-2 and anti-CD16mAb also induced
split anergy by significantly decreasing the NK cell cytotoxicity
while increasing the cytokine secretion capabilities of NK cells
[17,18,19,20]. Furthermore, IL-2 rescued anti-CD16 mAb
mediated apoptosis induced in a subset of NK cells [19]. Loss of
cytotoxicity in NK cells was exacerbated when NK cells were
either treated with F(ab)’2 fragment of anti-CD16 mAb or treated
with a combination of MHC-Class I and anti-CD16 mAb while
the same treatments resulted in an increased secretion of cytokines
[17,20]. These results suggested that increase in signaling load on
NK cells is likely to result in a decrease in cytotoxicity while
increasing secretion of cytokines by the NK cells. Therefore, three
distinct functional outcomes could be observed in NK cells which
have either interacted with sensitive tumor-target cells or treated
with anti-CD16 mAb in the presence of IL-2 treatment, namely; 1-
Loss of cytotoxicity, 2-gain in the ability to secrete cytokines and 3-
death in a subset of NK cells. Whether these functions are carried
out by the same NK cell subsets or there are distinct subsets of NK
cells with distinct functional capabilities require further studies.
However, similar to T cells, NK cells can also be functionally
anergized or induced to undergo cell death during increased
signaling load.
Increased activity of NFkB in tumor cells was found to be
inhibitory for the function of NK cells since blocking NFkBi n
tumor cells made these cells susceptible to lysis by the NK cells
[21,22]. Therefore, to determine which subpopulations of immune
effectors were able to protect DPSCs/MSCs against NK cell
mediated lysis, we undertook studies to first identify the subset of
immune effectors, which was able to increase NFkB in stem cells
substantially, and to determine their role in the overall increase in
the survival and function of stem cells.
It is quite well established in tumor immunotherapy that certain
effectors of the myeloid arm of the immune system induce
resistance in tumor cells and cause suppression of NK cell
mediated cytotoxicity [23]. Monocytes, an important subset of the
myeloid arm of the immune effectors are known to be the major
inducers of resistance in tumor cells and are shown to significantly
aid in the progression of cancer in tumor-bearing hosts [23,24,25].
However, the mechanisms by which monocytes contribute to the
progression of cancer have not been fully elucidated yet.
Therefore, studies reported in this paper may also have the
potential to shed light on this very important question. Our recent
findings indicated that monocytes protect oral tumors via NFkB
dependent and independent pathways (manuscript submitted). In
addition, the role of monocytes in suppression of NK cell mediated
cytotoxicity against MSCs/DPSCs has not been explored yet.
Furthermore, whether a unique subset or all monocytes mediate
suppression of NK cell mediated cytotoxicity against MSCs needs
to be explored. Studies reported in this paper are significant in
several ways. First, we demonstrate that both allogeneic and
autologous NK cells are capable of lysing stem cells significantly
and that lysis can be blocked by the treatment of NK cells with
anti-CD16 antibody. Second, either the total populations of
monocytes or those depleted of CD16
+ subsets are capable of
increasing survival of DPSCs/MSCs against NK cells in three way
interactions, raising the overall secretion of key cytokines
responsible for the resistance and differentiation of stem cells
and protection against NK cell mediated cytotoxicity. Therefore,
the effect of monocytes on NK cells are reminiscent of the effect of
anti-CD16 mAb or target mediated induction of split anergy in
NK cells [16,19]. Thus, the protection of stem cells against NK cell
lysis is partly due to the direct induction of resistance of stem cells
by monocytes and indirectly by serving as a shield to protect lysis
of stem cells by the NK cells since they too are greatly susceptible
to NK cell mediated lysis in a three way interaction.
Finally, by delineating the optimal cell-cell interaction required
for the protection of stem cells from NK cell mediated cytotoxicity,
we can design strategies to successfully implant either allogeneic or
autologous stem cells in different tissue engineering applications.
Overall, our studies demonstrate that monocytes are important
catalysts of survival for different cellular subsets, and protect stem
cells from NK cell mediated lysis, thereby elevating the collective
functions of the cells.
Materials and Methods
Cell Lines, Reagents, and Antibodies
HEp2 cells were obtained from ATCC and were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% FBS. MSCs were purchased from Clonetics and cultured
with the basal medium provided by the manufacturer. DPSCs
were isolated as described previously [26] and they were cultured
in complete DMEM supplemented with 10% FBS. Recombinant
IL-2 was obtained from the NIH repository. The NK, CD16
+ and
CD16
2 monocyte purification kits were obtained from Stem Cell
technologies (Stem Cell, Vancouver, Canada). The ELISA kits for
IFN-c, VEGF and IL-6 were purchased from R&D Systems
(Minneapolis, MN). The TNF-a ELISA was developed in our
laboratory and reported previously [19]. The multiplex cytokine
array kit was purchased from R&D Systems. The Fluorescein
Isothiocyanate (FITC) conjugated Annexin V/Propidium Iodide
(PI) kit was purchased from Coulter Immunotech (Miami, FL).
Purification of NK cells, Total monocytes and CD16
2
Monocytes
PBMCs from healthy donors were isolated as described before
[16]. Briefly, peripheral blood lymphocytes were obtained after
Ficoll-hypaque centrifugation and adherence to the plate for
1 hour. Purified NK cells were negatively selected by using an NK
cell isolation kit. The purity of NK cell population was found to be
greater than 90% based on flow cytometric analysis of anti-CD16
antibody stained cells. The levels of CD3
+ T cell staining in
purified population of NK cells remained low at 2.4%61%,
similar to that obtained by the non-specific staining using isotype
control antibody throughout the experimental procedures. The
adherent subpopulation of PBMCs was detached from the tissue
culture plates and the total population of monocytes and those
depleted of CD16
+ subsets (CD16
2) were purified using isolation
kits obtained from Stem Cell Technologies (Vancouver, Canada).
Greater than 95% purity was achieved for each subset based on
flow cytometric analysis of CD14 and CD16 antibody stained
monocytes. Written informed consents approved by UCLA
NK Cells Kill Stem Cells
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donors and all the procedures were approved by the UCLA-IRB.
ELISA and Multiplex Cytokine Array kit
Single ELISAs were performed as described previously [13].
Fluorokine MAP cytokine multiplex kits were purchased from R&D
Systems (Minneapolis, MN) and the procedures were conducted as
suggested by the manufacturer. To analyze and obtain the cytokine
concentration, a standard curve was generated by either two or three
fold dilution of recombinant cytokines provided by the manufacturer.
Analysis was performed using the Star Station software.
51Cr release cytotoxicity assay: The
51Cr release assay was
performed as described previously [22]. Briefly, MSCs or DPSCs
were co-cultured with irradiated (10 Gy) subsets of monocytes for 24–
48 hours before they were labeled with
51Cr for 1 hour, after which
they were washed and added to NK samples. In several experiments
monocytes were sorted out from the stem cell co-cultures before they
were labeled with
51Cr and added to the NK cells. 100% removal of
monocytes from the stem cells was achieved when the sorted samples
were checked either by microscopy or by flow cytometric analysis of
stained cells. After a 4 hour incubation period, the supernatants were
harvested and counted for released radioactivity. The percentage of
Figure 1. Potent lysis of MSCs and DPSCs by the Natural Killer cells; inhibition by anti-CD16 antibodies. Highly purified NK cells were
left untreated or treated with anti-CD16 mAb (3 mg/ml), IL-2 (1000 u/ml), or a combination of IL-2 (1000 u/ml) and anti-CD16 mAb (3 mg/ml) for 8–
12 hours before they were added to the
51Cr labeled MSCs (Fig. 1A)o r
51Cr labeled DPSCs (Fig. 1B)o r
51Cr labeled K562 (Fig. 1C) at different
effector to target (E:T) ratios. After 4 hours of incubation the supernatants were removed and the released radioactivity was counted by a c counter.
% cytotoxicity was determined as indicated in the Materials and Methods section. One of five representative experiments is shown in this figure.
doi:10.1371/journal.pone.0009874.g001
Figure 2. Decreased killing of MSCs by NK cells when MSCs were co-cultured with monocytes prior to the addition of NK cells.
Monocytes were purified from PBMCs and irradiated as indicated in the Material and Methods section. MSCs (1610
6 cells/plate) were cultured with
the irradiated monocytes (monocyte: MSC ratio of 1:1) for 24–48 hours before they were removed from the plates, washed and labeled with
51Cr and
used as targets in the cytotoxicity assays against NK cells. The NK samples were either left untreated (Fig. 2A) or treated with anti-CD16 mAb (3 mg/
ml) (Fig. 2B), IL-2 (1000 u/ml) (Fig. 2C), or a combination of IL-2 (1000 u/ml) and anti-CD16 mAb (3 mg/ml) (Fig. 2D) for 24–48 hours before they
were added to
51Cr labeled MSCs at different effector to target (E:T) ratios. Supernatants were removed after 4 hours of incubation and the released
radioactivity counted by a c counter. % cytotoxicity was determined as indicated in the Material and Methods section. One of three representative
experiments is shown in this figure.
doi:10.1371/journal.pone.0009874.g002
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+ subsets of monocytes protect MSCs and DPSCs against NK cell mediated
cytotoxicity. MSCs (Fig. 3A) or DPSCs (Fig. 3B)e a c ha t1 610
6 cells/plate were co-cultured with highly purified and irradiated total monocytes or
CD16
2 subsets of monocytes at 1:1 MSCs to monocyte ratio for 24–48 hours before they were detached, washed and labeled with
51Cr and added to
untreated or IL-2 (1000 u/ml) pre-treated or anti-CD16mAb (3 mg/ml) pre-treated, or a combination of IL-2 (1000 u/ml) and anti-CD16 mAb (3 mg/ml)
pre-treated NK cells at different E:T ratios. NK cells were pre-treated as indicated for 24–48 hours before they were added to the co-cultures of
monocytes with MSCs. After 4 hours of incubation the supernatants were removed and the released radioactivity counted by a c counter. %
cytotoxicity was determined at different E:T ratio, and LU30/10
6 cells were calculated using the inverse of the number of effectors needed to lyse 30%
of the MSCs or DPSCs X100. Both autologous and allogeneic DPSCs (Fig. 3C)a t1 610
6 cells/plate were cultured with highly purified and irradiated
NK Cells Kill Stem Cells
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% Cytotoxicity ~ Experimental cpm { spontaneous cpm
Total cpm { spontaneous cpm
LU 30/10
6cells were calculated using the inverse of the number
of effector cells needed to lyse 30% of tumor target cells X100.
Surface and DNA Staining and apoptosis assay
Staining was performed by labeling the cells with antibodies or
propidium iodide and Annexin V as described previously [19] [16,27].
Luciferase reporter assay
Transfections were performed using NFkB Luciferase reporter
vector [28] and Lipofectamine 2000 reagent (Invitrogen, CA) in
Opti-MEM media (Invitrogen, CA) for 18 hours after which they
were adhered to the plate overnight before different immune
effectors at 1:1 Effector to target ratios were added. The cells were
then lysed with lysis buffer and the relative Luciferase activity was
measured using the Luciferase assay reagent kit obtained from
Promega (Madison, WI).
Statistical analysis
An unpaired, two-tailed student t- test was performed for the
statistical analysis. One way ANOVA with a Bonferroni post test
was used to compare the different groups.
Results
MSCs and DPSCs were selected based on their
phenotypic and functional properties
MSCs were CD166
+CD105
+CD99
+CD34
2CD45
2and CD14
2
based on the flow cytometric analysis (data not shown). In addition,
MSCs were capable of differentiating to osteogenic, chondrogenic and
adipogenic lineages (data not shown, www.clonetics.com). DPSCs were
isolated as described previously [26] and is shown by us and by others
[10] to have osteogenic, chondrogenic and adipogenic properties.
IL-2 activated NK cells are potent inducers of cell death in
MSCs
Highly purified human NK cells were treated with and without IL-
2 for 8–12 hours before they were added to
51Cr labeled MSCs
(Fig. 1A) or DPSCs (Fig. 1B) or NK sensitive K562s (Fig. 1C). The
addition of freshly isolated untreated NK cells had lower cytotoxic
activity againstMSCs (Fig. 1A), DPSCs(Fig. 1B) and K562s (Fig. 1C).
However, activation with IL-2 increased cytotoxicity substantially
and resulted in a significant lysis of stem cells (p,0.05) (Fig. 1).
Anti-CD16 antibody induces death in a subset of
untreated and IL-2 treated NK cells and inhibits NK cell
mediated lysis of MSCs and DPSCs
NK cells were left untreated or treated with anti-CD16 antibody
and/or IL-2 for 8-12 hours before they were added to
51Cr labeled
MSCs or DPSCs. As shown in a number of previous studies
[18,19,20] and below, anti-CD16 mAb treatment induced death
in a subset of NK cells and inhibited NK cell cytotoxicity against
MSCs and DPSCs (p,0.05) (Fig. 1). The addition of the
combination of IL-2 and anti-CD16 mAb treatment also induced
death in a subset of NK cells and inhibited NK cell cytotoxicity
against MSCs and DPSCs when compared to IL-2 activated NK
cells (p,0.05) (Fig. 1).
Figure 4. Monocytes prevent NK cell death induced by anti-
CD16mAb. NK cells were labeled with FITC before they were either left
untreated or treated with anti-CD16 mAb (3 mg/ml), IL-2 (1000 u/ml), or
a combination of IL-2 (1000 u/ml) and anti-CD16 mAb (3 mg/ml) and
immediately added to monocytes at 1:1 (NK: monocyte) ratios. After an
overnight incubation the levels of cell death in NK cells were
determined by flow cytometric analysis of Propidium Iodide stained
cells. FITC labeled NK cells were gated to determine the levels of PI
stained NK cells. 10,000 events were analyzed for each sample. One of
three representative experiments is shown in this figure.
doi:10.1371/journal.pone.0009874.g004
total monocytes or CD16- subsets of monocytes at 1:1 DPSCs to monocytes for 24–48 hours before they were detached, washed and labeled with
51Cr
and added to untreated or IL-2 (1000 u/ml) pre-treated or anti-CD16mAb (3 mg/ml) pre-treated, or a combination of IL-2 (1000 u/ml) and anti-CD16
mAb (3 mg/ml) pre-treated NK cells at different E:T ratios. NK cells were pre-treated as indicated for 24–48 hours before they were added to the co-
cultures of monocytes with DPSCs. After 4 hours of incubation the supernatants were removed and the released radioactivity counted by a c counter.
% cytotoxicity was determined, and LU30/10
6 cells were calculated using the inverse of the number of effectors needed to lyse 30% of DPSCs X100.
doi:10.1371/journal.pone.0009874.g003
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DPSCs
Monocytes were purified from PBMCs and irradiated as
indicated in the Material and Methods section. MSCs and DPSCs
were co-cultured with allogeneic irradiated monocytes for 24–
48 hours before they were labeled with
51Cr and used in the
cytotoxicity assays against NK cells. NK cells were left untreated
or pre-treated with anti-CD16 antibody and/or IL-2 for 24–
48 hours before they were used in the cytotoxicity assays against
MSCs and DPSCs. The addition of monocytes to MSCs
significantly protected the MSCs (Fig. 2 and 3A) and DPSCs
(Fig. 3B) from NK cell mediated cytotoxicity (p,0.05). Significant
inhibition of NK cell cytotoxicity by monocytes could be observed
against untreated and IL-2 treated NK samples (p,0.05) (Figs. 2
and 3). Monocytes also increased the levels of alkaline phosphatase
staining in MSCs and prevented decrease in alkaline phosphatase
expression induced by IL-2 activated NK cells (data not shown).
Untreated or anti-CD16 antibody treated live or irradiated
monocytes were not able to mediate cytotoxicity against MSCs,
DPSCs or K562 cells (data not shown). Overall, these experiments
indicated that monocytes protect MSCs and DPSCs against NK
cell mediated lysis. The reason cytotoxicity was shown both as
percentage of killing over different E:T ratios (Figs. 1 and 2) and as
Lu30/10
6 cells (Fig. 3) is to demonstrate the clear relationship
between cytotoxicity and calculated lytic units which will be used
from here on after.
Both the total populations of monocytes and those
depleted of CD16
+ subsets prevented NK cell mediated
cytotoxicity against MSCs and DPSCs
Since unbound anti-CD16 antibody or shed antibody from the
NK cells could affect the small subpopulation of CD16
+
monocytes by modulating their function, we opted to sort out
this small subset of monocytes from the total population of
monocytes (16
2) and compared their function to the activity of
monocytes containing both the CD16
+ and CD16
2 subpopula-
Figure 5. Monocytes synergize with NK cells and MSCs to induce IL-6, TNF-a, VEGF and IFN-c. MSCs (1610
5 cells/well) were co-cultured
with and without irradiated Monocytes at 1:1 MSCs to monocytes for 24–48 hours before untreated or IL-2 (1000 u/ml) pre-treated or anti-CD16mAb
(3 mg/ml) pre-treated, or a combination of IL-2 (1000 u/ml) and anti-CD16 mAb (3 mg/ml) pre-treated NK cells at 1:1 NK: monocyte ratios were added
to the MSC: moncyte co-cultures. NK cells were pre-treated as indicated for 24–48 hours before they were added to the co-cultures of monocytes and
MSCs. NK samples were also cultured in the absence of monocytes and MSCs. After 24–48 hours of the addition of NK cells the supernatants were
removed from the cultures and the levels of IL-6 (Fig. 5A), TNF-a (Fig. 5B), VEGF (Fig. 5C), and IFN-c (Fig. 5D) were determined using multiplex
cytokine array kit. The results were also confirmed for each individual cytokine using single ELISAs (data not shown). One of three representative
experiments is shown in this figure.
doi:10.1371/journal.pone.0009874.g005
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cytotoxicity against MSCs and DPSCs. Both total population and
CD16
+ depleted subsets of monocytes could significantly prevent
NK cell mediated lysis of MSCs (Fig. 3A) and DPSCs (Fig. 3B and
3C). Similar results were obtained in regards to the protection of
DPSCs by monocytes against NK cell mediated lysis when the
function of NK cells and monocytes was assessed with both
allogeneic and autologous DPSCs (Fig. 3C). Furthermore, the
removal of CD16 antibody by extensive washings of NK cells
before their culture with monocytes and stem cells had similar
results to those which were left unwashed and used in co-cultures
with monocytes and stem cells (data not shown).
Monocytes prevent anti-CD16 antibody mediated NK cell
death
Since monocytes were capable of protecting MSCs and DPSCs
from NK cell mediated lysis we reasoned that they may also
protect NK cells from undergoing cell death. Therefore, to
investigate the protection of NK cells by monocytes, untreated or
IL-2 treated and/or anti-CD16mAb treated NK cells were co-
cultured with monocytes immediately after purification and
treatment, and their viability was determined after an overnight
incubation. As shown in Fig. 4 monocytes prevented NK cell death
induced by anti-CD16 antibody in the presence and absence of IL-
2 treatment (p,0.001). Therefore, monocytes are potent inducers
of NK cell survival.
Monocytes increase IFN-c, IL-6, TNF-a and VEGF secretion
substantially when cultured with and without NK cells
and MSCs or NK cells and DPSCs
Irradiated monocytes were added to MSCs for 24–48 hours
before the addition of untreated or IL-2 pre-treated and/or anti-
CD16 antibody pre-treated NK cells. After 24–48 hours of
incubation with NK cells the supernatants were removed, and
the levels of IFN-c, IL-6, TNF-a and VEGF secretion were
determined using both multiplex cytokine array assay and single
ELISAs (Fig. 5). Monocytes increased the secretion of IL-6 and
TNF-a in co-cultures with either NK cells or with MSCs (p,0.05)
(Figs. 5A and 5B). However, the highest increase was obtained
when monocytes were added to NK and MSCs (p,0.05) (Figs. 5A
and 5B). As expected, IL-2 increased the secretion of TNF-a and
IL-6 moderately in NK cells and the combination of IL-2 and anti-
CD16 mAb had synergistic effect on the release of TNF-a by the
NK cells (Figs. 5A and 5B). The addition of monocytes increased
synergistically the secretion of IL-6 and TNF-a in all treated NK
samples (p,0.05) (Figs. 5A and 5B). MSCs induced synergistically
the secretion of IL-6 when cultured with NK samples (p,0.05)
(Fig. 5A). Secretion of IL-6 and TNF-a were significantly
Figure 6. Total monocytes or CD16
2 subsets of monocytes synergize with NK cells and MSCs or DPSCs to induce IFN-c secretion.
MSCs (Fig. 6A) or DPSCs (Fig. 6B)a t1 610
5 cells/well were co-cultured with highly purified and irradiated total monocytes or CD16
2 subsets of
monocytes at 1:1 MSCs or DPSCs to monocyte ratios for 24–48 hours before untreated or IL-2 (1000 u/ml) pre-treated or anti-CD16mAb (3 mg/ml)
pre-treated, or a combination of IL-2 (1000 u/ml) and anti-CD16 mAb (3 mg/ml) pre-treated NK cells at 1:1 MSCs or DPSCs to NK cells were added. NK
cells were pre-treated as indicated for 24–48 hours before they were added to the co-cultures of monocytes and MSCs or DPSCs. After 24–48 hours of
the addition of NK cells the supernatants were removed and subjected to specific ELISA for IFN-c. One of four representative experiments is shown in
this figure.
doi:10.1371/journal.pone.0009874.g006
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when compared to those in the absence of monocytes (p,0.05)
(Figs. 5A and 5B). However, the levels of IL-6 and TNF-a reach
plateau when monocytes were added to untreated or anti-CD16
mAb and/or IL-2 treated NK cells and MSCs (Figs. 5A and 5B).
Secretion of VEGF was only observed in samples containing
MSCs, and monocytes further increased secreted VEGF by MSCs
(p,0.05) (Fig. 5C). Finally, as expected IL-2 treated NK cells
secreted moderate amounts of IFN-c which were synergistically
increased when co-cultured in the presence of MSCs (p,0.05)
(Fig. 5D). The addition of anti-CD16 mAb in combination with
IL-2 to NK cells in the absence of MSCs increased secretion of
IFN-c when compared to IL-2 alone treated NK cells in the
absence of MSCs. IFN-c secreted levels remained similar between
IL-2 alone and IL-2 and anti-CD16 mAb treated NK cells
cultured with MSCs (Fig. 5D). Monocytes added to IL-2 or IL-2
and anti-CD16 antibody treated NK cells in the absence of MSCs
or those in the presence of MSCs, synergistically increased the
levels of secreted IFN-c (p,0.05) (Fig. 5D). However, the highest
increase in IFN-c release was seen when monocytes were added to
IL-2 or IL-2 and anti-CD16 mAb treated NK cells with MSCs
(Fig. 5D). These results indicated that monocytes increased all of
the above-mentioned cytokines in co-cultures with MSCs, and
further synergized with IL-2 or IL-2 and anti-CD16 mAb treated
NK samples to increase the release of cytokines in the co-cultures
of NKs and MSCs. Similar results were obtained when NK cells
were co-cultured with monocytes and DPSCs (Fig. 6).
Total populations of monocytes or those depleted of
CD16
+ subset trigger significant release of IFN-c by NK
cells in a three way interaction with MSCs or DPSCs
Purified irradiated total monocytes or those depleted of CD16
+
subsets were each co-cultured with MSCs or DPSCs for 24–
48 hours before untreated or IL-2 and/or anti-CD16 mAb pre-
treated NK cells were added. The incubation was then continued
for another 24–48 hours before the supernatants were removed
and subjected to specific ELISAs for IFN-c (Fig. 6). The
differences in secretion of IFN-c between the two monocyte
samples were either moderate or very slight when NK, monocytes
and MSCs were all present in the co-cultures (Figs. 6A and 6B).
Monocytes cultured with or without MSCs (Fig. 6A) and DPSCs
(Fig. 6B) increased secretion of IFN-c substantially when added to
IL-2 or IL-2 and anti-CD16 antibody treated NK cells. Since
monocytes alone or monocytes cultured with MSCs or DPSCs did
not have any effect on IFN-c secretion in all the experiments
tested, we did not include them in Fig. 6 (data not shown).
Protection of DPSCs from NK cell mediated cytotoxicity
could still be seen when monocytes were sorted out
from DPSCs before they were exposed to NK cells
Purified total population of monocytes or those depleted of
CD16
+ subsets were each co-cultured with DPSCs for 24–
48 hours, before they were sorted out and removed from DPSCs.
DPSCs were then labeled with
51Cr and cultured with untreated
or IL-2 and/or anti-CD16 mAb pre-treated NK cells. As shown in
Fig. 7A, protection from NK cell mediated lysis could still be seen
when monocytes were removed from DPSCs before their exposure
to NK cells. However, this effect was not specific to monocytes
alone since the addition of either T cells (Fig. 7B) or B cells
(Fig. 7C) to DPSCs and their removal after 24–48 hours were also
protective against NK cell mediated lysis of DPSCs.
Monocytes and T cells are targets for NK cell mediated
lysis
Since significant IFN-c secretion could also be obtained in the
co-cultures of IL-2 treated NK cells with monocytes we
determined whether they were also targets of NK cell mediated
lysis. As shown in Fig. 8 both monocytes and T cells were targets of
Figure 7. Decreased lysis of DPSCs by NK cells were seen when monocytes, T cells and B cells were sorted out from co-cultures of
DPSCs with these cells before the addition of NK cells. Purified total population of monocytes or those depleted of CD16
+ subsets (Fig. 7A),
purified T cells (Fig. 7B) and purified B cells (Fig. 7C) were each co-cultured with 1610
6 DPSCs per plate at 1:1 ratios for 24–48 hours, before the
subsets of monocytes or T cells or B cells were sorted out and removed from DPSCs. Sorted DPSCs from monocytes, T cells and B cells were then
labeled with 51Cr, washed and added to untreated or IL-2 (1000 u/ml) pre-treated or anti-CD16mAb (3 mg/ml) pre-treated, or a combination of IL-2
(1000 u/ml) and anti-CD16 mAb (3 mg/ml) pre-treated NK cells. After 4 hours of incubation the supernatants were removed and the released
radioactivity counted by a c counter. % cytotoxicity was determined at different E:T ratio, and LU30/10
6 cells were calculated using the inverse of the
number of effectors needed to lyse 30% of the DPSCs X100.
doi:10.1371/journal.pone.0009874.g007
Figure 8. Monocytes and T cells are targets for NK cell mediated
lysis. Highly purified NK cells were left untreated or treated with anti-
CD16 mAb (3 mg/ml), IL-2 (1000 u/ml), or a combination of IL-2 (1000 u/
ml) and anti-CD16 mAb (3 mg/ml) for 8–12 hours before they were added
to the
51Cr labeled DPSCs, or
51Cr labeled monocyts or
51Cr labeled T cells
at different effector to target (E:T) ratios. After 4 hours of incubation the
supernatants were removed and the released radioactivity counted by a c
counter. % cytotoxicity was determined at different E:T ratio, and LU30/
10
6 cells was calculated using the inverse of the number of effectors
needed to lyse 30% of either DPSCs, monocytes or T cells X100. One of
three representative experiments is shown in this figure.
doi:10.1371/journal.pone.0009874.g008
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could also be obtained in supernatants removed from co-cultures
of NK cells with monocytes (Fig. 9A) or T cells (Fig. 9A) or B cells
(Fig. 9B). One distinction was in the magnitude of secreted IFN-c
by the NK cells treated with IL-2 and anti-CD16 mAb in which
those cultured with monocytes secreted higher levels than those
cultured with either T cells or B cells (Fig. 9).
Monocytes are major inducers of NFkB activity in
epithelial cells
Purified subpopulations of the immune effectors, namely, highly
purified monocytes, Natural Killer cells, PMNs and total
populations of peripheral blood mononuclear cells (PBMCs) and
peripheral blood lymphocytes (PBLs) were each co-cultured with
NFkB reporter transfected HEp2 cells (Fig. 10), and the levels of
NFkB activity were determined after 4 hours of incubation. As
shown in Fig. 10 monocytes induced the highest increase in NFkB
activity whereas all the other populations including NK cells had
minimal or no effect on NFkB activity (p,0.05).
Discussion
Successful transplantation of stem cells in an immunocompe-
tent host will eventually depend on the ability of transplanted
stem cells to survive during their interaction with the host
immune effectors. Although a number of previous studies have
attributed a lack of immunogenicity to stem cells, others have
shown significant lysis of these cells by the cytotoxic immune
effectors [4,6,7]. Therefore, detailed analysis of immune cell
interaction with stem cells is important, and should provide the
basis for designing novel strategies to increase the viability and
function of stem cells in different tissue engineering applications.
It is therefore, important to determine the potential mechanisms
by which stem cells can be protected from the lysis by cytotoxic
immune effectors.
To study the detailed function of cytotoxic immune effectors
against stem cells we purified human NK cells and studied their
effect on MSCs and DPSCs. In addition, we determined the
interaction of NK cells with other subsets of immune effectors
during their interaction with stem cells. In agreement with
previous studies we also show in this report that NK cells can
target and kill MSCs significantly. Indeed, when compared to
K562 lysis, NK cells can also mediate significant lysis of MSCs
(Figs. 1 and 2) and DPSCs. Moreover, we demonstrate for the first
time that DPSCs are also targets of NK cell mediated killing, and
that stem cells in general have exquisite sensitivity to NK cell
mediated lysis. In support of this notion, we have recently
determined that human embryonic stem cells are the most
sensitive stem cells to NK cell mediated cytotoxicity when
compared to DPSCs (manuscript in preparation). In addition,
autologous DPSCs are as good of a target for NK cell mediated
lysis as the allogeneic DPSCs.
Figure 9. Total monocytes or T cells or B cells synergize with NK cells and DPSCs to induce IFN-c secretion. DPSCs (1610
5 cells/well)
were co-cultured with highly purified total monocytes (Fig. 9A and 9B) or T cells (Fig. 9A) or B cells (Fig. 9B) at 1:1 DPSCs to monocyte or T cell or
B cell ratios for 24–48 hours before untreated or IL-2 (1000 u/ml) pre-treated or anti-CD16mAb (3 mg/ml) pre-treated, or a combination of IL-2
(1000 u/ml) and anti-CD16 mAb (3 mg/ml) pre-treated NK cells at 1:1 DPSCs to NK cells were added. NK cells were pre-treated as indicated for 24–
48 hours before they were added to the co-cultures of monocytes or T cells or B cells and DPSCs. After 24–48 hours of the addition of NK cells the
supernatants were removed and subjected to specific ELISAs for IFN-c. One of four representative experiments is shown in this figure.
doi:10.1371/journal.pone.0009874.g009
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percentage of MSCs and DPSCs when compared to untreated NK
cells, although a range of 20% to 70% cytotoxicity could be
observed by untreated NK cells depending on the donor NK cells
used to lyse stem cells (data not shown). In addition, anti CD16
antibody treated NK cells lost their cytotoxic function against
MSCs and DPSCs since this treatment resulted in anergy as well
as the death of a subset of NK cells and prevention of cytotoxicity
against MSCs and DPSCs. Moreover, significant induction of
IFN-c secretion could be observed in supernatants removed from
the co-cultures of either IL-2 or IL-2 and anti-CD16 mAb treated
NK cells with MSCs and DPSCs.
When MSCs and DPSCs were cultured with either viable or
irradiated monocytes before they were exposed to IL-2 treated NK
cells a significant decrease in NK cell mediated cytotoxicity could
be observed. Interestingly, significant lysis of MSCs and DPSCs by
untreated NK cells was also significantly and reproducibly blocked
by the addition of monocytes (Fig. 2). To determine whether
decreased lysis of stem cells by NK cells was due to competitive
lysis of monocytes by NK cells we performed several experiments.
Indeed, we confirmed that monocytes were also lysed by NK cells
significantly. In addition, we found not only monocytes but also T
and B cells to be significant targets of NK cell mediated killing.
Furthermore, when we co-cultured stem cells with monocyte
subsets and sorted to remove the monocytes from the stem cells we
could still observe significant inhibition of NK cell mediated lysis,
arguing against the protection of stem cell lysis by NK cells being
solely on the bases of competitive lysis of monocytes. Therefore,
even though lysis of monocytes by the NK cells may in part
contribute to the prevention of NK cell lysis of stem cells,
interaction of monocytes with stem cells can also provide
resistance of stem cells against NK cell cytotoxicity. However,
this function was not specific to monocytes since the addition of T
and B cells to stem cells and their removal by sorting before their
culture with NK cells could also provide resistance of stem cells
against NK cell mediated cytotoxicity. Therefore, it is likely that
interaction of NK cells with stem cells in the presence of other
immune effectors is complex and it is governed by not only the
ability of NK cells to lyse other immune effectors, but also due to
increased resistance of stem cells to NK cell lysis after interaction
with subsets of immune effectors.
Decrease in NK cell lysis of MSCs and DPSCs was paralleled
with a significant induction of IFN-c in a stepwise manner. Indeed,
when MSCs or DPSCs were cultured with IL-2 treated NK cells
alone we could observe significant induction of IFN-c secretion.
However, the highest increase was seen when NK cells were
cultured with MSCs or DPSCs in the presence of monocytes.
Therefore, although decreased killing of stem cells by the NK cells
could be observed in the presence of monocytes, synergistic
secretion of IFN-c by the NK cells in the presence of monocytes
and stem cells could be observed, indicating a discordant
relationship between cytotoxicity and IFN-c secretion. This was
similar to the profiles which we had seen when NK cells were
treated with IL-2 and anti-CD16 antibody in which significant
decrease in cytotoxicity of NK cells could be observed in parallel
with increased secretion of IFN-c (Fig. 5, 6 and 9). We have
previously shown that IL-2 rescues NK cells from anti-CD16 mAb
mediated apoptosis [19], therefore, it is possible that monocytes
also contribute to rescue from apoptosis and increase in secretion
of IFN-c by the NK cells. Indeed, monocytes prevent anti-CD16
mediated NK cell apoptosis (Fig. 4). Rescue of NK cells from
apoptosis could be an important function of monocytes since 1-
monocytes are known to increase NFkB activity in the cells, and 2-
lysis of monocytes by the NK cells could result in activation and
increased resistance of NK cells to cell death. In this respect T and
B cells can also provide increased survival of NK cells since they
too are targets of NK cell killing, but they are not capable of
inducing NFkB in epithelial cells to the levels which were induced
by monocytes. In addition, even though T and B cells could cause
resistance of stem cells to NK cell mediated cytotoxicity, they
could not raise the levels of IFN-c secretion by the IL-2 and anti-
CD16 mAb treated NK cells to the levels which were observed
when these cells were cultured with monocytes and stem cells
(Fig. 9).
These observations prompted us to speculate regarding the
significance of interaction of monocytes with NK cells and stem
cells. It is plausible that monocytes serve as not only effectors
which provide survival for NK cells and stem cells but also they
may serve as shields against NK cell lysis of stem cells. Similar to
anti-CD16 antibody mediated effect on IL-2 treated NK cells,
monocytes too can shield stem cells from killing by the NK cells
by increasing the total IFN-c release by the NK cells while
decreasing the cytotoxic function of NK cells (split anergy),
resulting in an increased protection and differentiation of stem
cells. Indeed, monocytes also increased TNF-a, IL-6 and VEGF
secretion in the co-cultures of stem cells with NK cells which
could further augment induction of NFkB and increased
differentiation of stem cells. The shielding effect of monocytes
could be a more generalized function of immune effectors since
NK cells can also target T and B cells. This may have significant
implications regarding the role of NK cells in not only limiting
inflammation, but also the significance of other immune effectors
Figure 10. Monocytes are potent inducers of NFkB activity in
HEp2 cells. HEp2 cells were transfected with NFkB luciferase reporter
vector before they were co-cultured with monocytes, purified NK cells,
peripheral blood lymphocytes (PBLs), polymorphonuclear (PMNs) and
peripheral blood mononuclear cells (PBMCs) at 1:1 ratio. After 4 hours
of incubation the fold induction of NFkB activity in the samples was
determined over the control HEp2 cells in the absence of immune
effectors.
doi:10.1371/journal.pone.0009874.g010
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against stem cells in order to raise maximally the secretion of key
cytokines for speedy and optimal differentiation of stem cells
during inflammation. This is precisely what is observed in cancer
patients in whom global decrease in NK, cytotoxic T cells and
monocytes have all been reported [29]. In addition, the increase
in IFN-c secretion by NK cells should provide the initial steps in
increasing antigen specific functions of T and B cells and
initiation of adaptive immunity.
We have recently observed an NFkB independent rescue of oral
epithelial cells by monocytes (manuscript in prep). Therefore, it is
likely that monocytes elevate survival of MSCs and DPSCs
through NFkB dependent and independent pathways. In addition,
both the total population of monocytes and those depleted of
CD16
+ subsets were able to increase NFkB and survival of oral
epithelial cells (manuscript in prep) and MSCs resulting in an
increase in cytokine secretion.
We have previously reported that rescue from cell death is
governed by inverse induction of NFkB and JNK and decreased
secretion of IgFbp6 in epithelial cells [26,30]. [31]. Whether
monocytes prevent stem cell death through similar mechanisms
should await future investigation.
Our previous work demonstrated the decoupling of NK cell
cytotoxicity from cytokine secretion [16]. The cytotoxic function
of non-dissociated NK-tumor cell conjugates remained very low
and did not increase when supplemented with IL-2 although they
proliferated and secreted higher amounts of TNF-a and IFN-c in
the supernatants [16]. In contrast, NK cells dissociated from the
target conjugates exhibited more cytotoxic activity, but they
proliferated poorly and secreted lower levels of TNF-a or IFN-c
following IL-2 treatment. More importantly, a fraction of NK cells
in non-dissociated NK-tumor conjugates were programmed for
cell death by apoptosis [16]. Furthermore, the addition of intact
and F(ab)’
2 fragment of anti-CD16 antibodies in combination with
IL-2 significantly and reproducibly inhibited the cytotoxic function
of NK cells, but the NK cells secreted relatively higher amounts of
IFN-c [18,19,20]. As mentioned above, we observed a similar
trend when monocytes were added to MSCs/DPSCs and the IL-2
treated NK cells. This function of anti-CD16 receptor antibody
and monocytes therefore can be exploited to decrease rejection of
stem cells by the NK cells. Indeed, for optimal engraftment of stem
cells one may require to target both cytotoxic NK and T cells and
in this regard the use of the combination of anti-CD16 antibody
and OKT3 antibody should theoretically achieve this objective.
We are currently using this strategy to improve engraftment of
stem cells in pulp tissues.
Given the high sensitivity of stem cells to NK cell cytotoxicity, it
is possible that significant elevation in NK cell signaling by MSCs
and subsequent initiation of signaling for anergy and cell death of
a subset of NK cells contribute to the observed suppression of NK
cell cytotoxicity. Indeed, significant down modulation of NK cell
receptors NKp30, NKp44 and NKG2D was also observed after
interaction of NK cells with MSCs [6]. Receptor down-
modulation could likely be a mechanism to limit the levels of
signaling for the survival of the NK cells. Therefore, the
suppression of NK cell cytotoxic function observed by MSCs
could well be due to over-stimulation of NK cells by the stem cells
and induction of cell death in NK cells. Therefore, the reason
MSCs were considered to prevent auto-immunity may be due to
their competitive binding and inactivation and removal of killer
NK cells. These possibilities are currently under investigation in
our laboratory.
Overall, studies reported in this paper provide evidence for an
important function of monocytes in protection of MSCs and
DPSCs from NK cell mediated lysis resulting in an increased
secretion of key cytokines for optimal survival, proliferation and
differentiation of stem cells in a three way interaction.
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